ETC
Exchange Traded Concepts’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $900K | Buy |
7,163
+136
| +2% | +$17.1K | 0.01% | 707 |
|
|
2025
Q1 | $777K | Sell |
7,027
-1,106
| -14% | -$122K | 0.01% | 683 |
|
|
2024
Q4 | $1.11M | Buy |
8,133
+169
| +2% | +$23.1K | 0.02% | 518 |
|
|
2024
Q3 | $918K | Buy |
7,964
+1,803
| +29% | +$208K | 0.02% | 544 |
|
|
2024
Q2 | $848K | Buy |
6,161
+429
| +7% | +$59.1K | 0.02% | 493 |
|
|
2024
Q1 | $791K | Sell |
5,732
-1,479
| -21% | -$204K | 0.02% | 491 |
|
|
2023
Q4 | $950K | Buy |
7,211
+26
| +0.4% | +$3.43K | 0.03% | 413 |
|
|
2023
Q3 | $808K | Sell |
7,185
-53
| -0.7% | -$5.96K | 0.02% | 433 |
|
|
2023
Q2 | $683K | Sell |
7,238
-222
| -3% | -$20.9K | 0.02% | 487 |
|
|
2023
Q1 | $755K | Sell |
7,460
-1,210
| -14% | -$122K | 0.02% | 368 |
|
|
2022
Q4 | $1.04M | Buy |
8,670
+147
| +2% | +$17.6K | 0.03% | 306 |
|
|
2022
Q3 | $905K | Sell |
8,523
-429
| -5% | -$45.6K | 0.03% | 291 |
|
|
2022
Q2 | $873K | Buy |
8,952
+552
| +7% | +$53.8K | 0.03% | 313 |
|
|
2022
Q1 | $788K | Sell |
8,400
-2,880
| -26% | -$270K | 0.02% | 374 |
|
|
2021
Q4 | $961K | Buy |
11,280
+5,130
| +83% | +$437K | 0.02% | 346 |
|
|
2021
Q3 | $590K | Buy |
6,150
+5,610
| +1,039% | +$538K | 0.02% | 452 |
|
|
2021
Q2 | $53K | Sell |
540
-229
| -30% | -$22.5K | ﹤0.01% | 871 |
|
|
2021
Q1 | $75K | Sell |
769
-316
| -29% | -$30.8K | ﹤0.01% | 765 |
|
|
2020
Q4 | $104K | Buy |
+1,085
| New | +$104K | ﹤0.01% | 665 |
|
|
2020
Q2 | – | Sell |
-29
| Closed | -$3K | – | 832 |
|
|
2020
Q1 | $3K | Buy |
+29
| New | +$3K | ﹤0.01% | 454 |
|